As­traZeneca, Sam­sung quit race to de­vel­op Rit­ux­an copy­cat as ri­vals crowd out the mar­ket

Six years af­ter As­traZeneca teamed up with Sam­sung Bi­o­log­ics to de­vel­op a biosim­i­lar for Roche’s rit­ux­imab, they are throw­ing in the tow­el.

The part­ners have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER